JPS6130555B2 - - Google Patents
Info
- Publication number
- JPS6130555B2 JPS6130555B2 JP53071517A JP7151778A JPS6130555B2 JP S6130555 B2 JPS6130555 B2 JP S6130555B2 JP 53071517 A JP53071517 A JP 53071517A JP 7151778 A JP7151778 A JP 7151778A JP S6130555 B2 JPS6130555 B2 JP S6130555B2
- Authority
- JP
- Japan
- Prior art keywords
- lysolecithin
- reaction
- pancreatin
- lecithin
- egg yolk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000006243 chemical reaction Methods 0.000 claims description 19
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 claims description 18
- 108010019160 Pancreatin Proteins 0.000 claims description 13
- 229940055695 pancreatin Drugs 0.000 claims description 12
- 102000002322 Egg Proteins Human genes 0.000 claims description 10
- 108010000912 Egg Proteins Proteins 0.000 claims description 10
- 235000013345 egg yolk Nutrition 0.000 claims description 10
- 210000000991 chicken egg Anatomy 0.000 claims description 9
- 210000004556 brain Anatomy 0.000 claims description 8
- 235000010469 Glycine max Nutrition 0.000 claims description 5
- 244000068988 Glycine max Species 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 229940088598 enzyme Drugs 0.000 claims description 3
- 210000000496 pancreas Anatomy 0.000 claims description 2
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 claims 1
- 229940062190 pancreas extract Drugs 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 13
- 229940067606 lecithin Drugs 0.000 description 13
- 235000010445 lecithin Nutrition 0.000 description 13
- 239000000787 lecithin Substances 0.000 description 13
- 238000000034 method Methods 0.000 description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 5
- 102000015439 Phospholipases Human genes 0.000 description 5
- 108010064785 Phospholipases Proteins 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000002198 insoluble material Substances 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 238000000638 solvent extraction Methods 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 229960002713 calcium chloride Drugs 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000005947 deacylation reaction Methods 0.000 description 2
- 229960003964 deoxycholic acid Drugs 0.000 description 2
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102000000496 Carboxypeptidases A Human genes 0.000 description 1
- 108010080937 Carboxypeptidases A Proteins 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 1
- 229940052299 calcium chloride dihydrate Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000020176 deacylation Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 235000021081 unsaturated fats Nutrition 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
【発明の詳細な説明】
本発明は、牛脳、豚脳、鶏卵黄または大豆ホモ
ジネートに、豚すい臓抽出酵素パンクレアチンを
作用させ、反応後、加熱処理することを特徴とす
る天然型リゾレシチン(リゾホスフアチジルコリ
ン)の製造法に関する。Detailed Description of the Invention The present invention provides natural lysolecithin (lysolecithin), which is characterized by reacting bovine brain, pig brain, chicken egg yolk, or soybean homogenate with pancreatin, an enzyme extracted from pig pancreas, and heat-treating it after the reaction. phosphatidylcholine).
従来、リゾレシチン類は免疫賦活作用及び平滑
筋の収縮に対する抑制作用等の有用な性質を有
し、この化合物にはα型及びβ型の構が存在する
とが知られている。そして天然型リゾレシチンの
製造法として、次に示す方法が知られている。 It has been known that lysolecithins have useful properties such as immunostimulatory effects and inhibitory effects on smooth muscle contraction, and that these compounds have α-type and β-type structures. The following method is known as a method for producing natural lysolecithin.
(i) 天然型レシチンを原料として、ダ毒ホスホリ
パーゼで処理することによりリゾレシチンを得
る方法。〔アンセル、ジイー・ビーおよびハウ
トーム、ジエー・エヌ(Ansell,G.B &
Howthome,J.N.),1964“ホスホリピド
(phospholipids)”,アムステルダム
(Amsterdam),95:エルサリア(Elserier)〕
(ii) 天然型レシチン(試薬レシチン)を原料とし
て、パンクレアチンで処理することによりリゾ
レシチンを得る方法。デイ・ジー・ハナハン
(D.J.Hanahan),ジヤーナル オブ バイオロ
ジカル・ケミストリー(J.Biol.Chem.)第195
巻、第199頁(1952)〕
しかし、上記方法において(i)では、用いるダ毒
ホスホリパーゼAが、非常に高価でかつ皮膚侵食
性を有し取り扱いが困難であり、また反応後の操
作も繁雑であるという欠点を有しており、また(ii)
では、用いる市販レシチンが大豆又は卵より抽出
分離したものであるが、その組成は極めて悪く、
本発明の原料となるレシチン含量は少なく高純度
のレシチンを得ようとする時は、非常に高価とな
る。またたとえば高純度のレシチンを用いたとし
ても、レシチン自体の不飽和脂肪残基が相当量酸
化されているため、パンクレアチンの活性が著し
く低下し、パンクレアチンによる脱アシル化にお
ける反応速度が非常に遅くなり、反応完結まで長
時間を要するなどの欠点がある。さらに、反応終
了後の操作において、市販レシチンを原料として
使用した場合、反応液は乳化状態となり、その後
の単離精製は、フオルヒ(Folch)分配及びカラ
ムクロマトグラフイー等の手段を用いなければな
らず非常に繁雑であるなどの欠点を有する。(i) A method for obtaining lysolecithin by using natural lecithin as a raw material and treating it with datoxin phospholipase. [Ansell, GB &
Howthome, JN), 1964 “Phospholipids”, Amsterdam, 95: Elserier] (ii) A method for obtaining lysolecithin by treating natural lecithin (reagent lecithin) with pancreatin. . DJ Hanahan, Journal of Biological Chemistry (J.Biol.Chem.) No. 195
Vol., p. 199 (1952)] However, in the above method (i), the datoxin phospholipase A used is very expensive and erosive to the skin, making it difficult to handle, and post-reaction operations are also complicated. (ii)
The commercially available lecithin used is extracted and separated from soybeans or eggs, but its composition is extremely poor.
Lecithin, which is a raw material for the present invention, has a low content and is very expensive if high purity lecithin is to be obtained. Furthermore, even if highly purified lecithin is used, a considerable amount of unsaturated fat residues in lecithin itself are oxidized, which significantly reduces the activity of pancreatin and significantly slows down the reaction rate of pancreatin-induced deacylation. It has disadvantages such as being slow and requiring a long time to complete the reaction. Furthermore, when commercially available lecithin is used as a raw material in the operation after the completion of the reaction, the reaction solution becomes an emulsified state, and subsequent isolation and purification must be performed using methods such as Folch partitioning and column chromatography. However, it has drawbacks such as being extremely complicated.
従つて上記のことから、方法(i)及び(ii)はいずれ
も、工業的製造法としては不向きである。 Therefore, from the above, both methods (i) and (ii) are unsuitable as industrial production methods.
本発明者等は、パンクレアチンを作用させ、レ
シチンよりリゾレシチンを工業的に容易に得る方
法について鋭意研究した結果、動植物の新鮮なレ
シチン含有組織、即ち、豚脳、牛脳、大豆、特に
鶏卵黄そのものを用いた場合はパンクレアチンの
酵素分解反応に於いて、その組織に含まれる補酵
素により相乗効果の結果、脱アシル化反応が非常
に円滑に進行すると共に、好収率で目的とするリ
ゾレシチンが生成することも見出した。また、反
応液に蛋白質及びオリゴペプチド等が含有されて
いることから、、フオルヒ((Folch)分配及びカ
ラムクロマトグラフイー等の操作でリゾレシチン
を単離するとは困難であがが、反応後加熱処理、
特に50〜120℃に加熱する蛋白質の熱変性工程を
導入するとにより、驚くべきことに変性を受けた
凝固蛋白質中に、定量的に目的とするリゾレシチ
ンが吸着され、その後、溶媒抽出等の操作により
容易に分離できる利点を有する。 As a result of intensive research on a method for industrially obtaining lysolecithin from lecithin by applying pancreatin, the present inventors found that it is possible to obtain lysolecithin from fresh lecithin-containing tissues of animals and plants, namely pig brain, cow brain, soybean, and especially chicken egg yolk. When used as such, in the enzymatic decomposition reaction of pancreatin, as a result of the synergistic effect of the coenzyme contained in the tissue, the deacylation reaction proceeds very smoothly, and the desired lysolecithin is produced in a high yield. was also found to be generated. In addition, since the reaction solution contains proteins, oligopeptides, etc., it is difficult to isolate lysolecithin using operations such as Folch partitioning and column chromatography, but post-reaction heat treatment ,
In particular, by introducing a thermal denaturation process for proteins heated to 50 to 120°C, surprisingly, the target lysolecithin is adsorbed quantitatively into the denatured coagulated proteins, and then through operations such as solvent extraction, It has the advantage of being easily separated.
本発明方法は上記知見に基づき完成されれたも
のであつて、天然型リゾレシチンの工業的製造法
として極めて優れた方法である。 The method of the present invention has been completed based on the above findings, and is an extremely excellent method for industrially producing natural lysolecithin.
以下さらに本発明を詳細に説明する。 The present invention will be further explained in detail below.
本発明を実施するにあたり、市販パンクレアチ
ン中には反応に必要なホスホリパーゼA2以外
に、少量のホスホリパーゼA1も存在ていると考
えられるが、一般に、この考素による影響はほと
んどないため、ホスホリパーゼA1の活性を失活
させるための加熱処理を、前もつて行なう必要は
ない。本発明方法は、まず牛脳、豚脳、鶏卵黄ま
たは大豆ホモジネートにパンクレアチンを添加
し、水中で反応させるのであるが、一般的によく
知られているように、使用するパンクレアチンに
含まれている前記以外の酵素、例えば、リボヌク
レアーゼ、アミラーゼ、トリプシン、キモトリプ
シン、リパーゼ並びにカルボキシペプチターゼA
及びB等の活性を抑制させるために、反応系に塩
化カルシウム及びデオキシコール酸を添加するの
が好ましい。そして上記反応は、一般に5〜50
℃、好ましくは35℃でPH7.0〜8.0の条件で行なわ
れ、一般に30分〜12時間で反応は終了する。例え
ば、原料として鶏卵黄を用いる場合、鶏卵黄1個
(18―20g)あたり0.1〜2.0gのパンクレアチンを
使用すると、約3時間で反応は終了する。反応
後、反応液は乳濁状態であるが、その大部分は蛋
白質と脂肪酸である。この反応液を100〜120℃で
加熱処理することより蛋白質を凝固させ、目的物
をその中に吸着させる。この凝固蛋白質を取
し、以下常法の手段を利用するとにより、目的物
を単離採取することができる。例えば、上記で得
られる凝固蛋白質を、メタノール、エタノール、
イソプロパノール等のアルコール類等に懸濁さ
せ、不溶蛋白質を除去し、得られる抽出溶液から
溶媒を減圧下に留去し、残渣にハロゲン化炭化水
素類、アルコール類及び水の混合溶媒を加え、有
機層を分取する。そして減圧下に溶媒を留去し、
更に脂肪酸、中性脂肪スフインゴミエリン及びオ
リゴペプチド類を除去するために、メタノール、
エタノール等のアルコール類及びn―ヘキサン又
はシクロヘキサン等の炭化水素系溶媒で抽出処理
を行なつた後、プロパノール及びエタノール等の
アルコール類で溶媒分離すれば、容易に高純度の
リゾレシチンを得るとができる。 In carrying out the present invention, in addition to the phospholipase A 2 necessary for the reaction, it is thought that a small amount of phospholipase A 1 is also present in commercially available pancreatin, but in general, this consideration has little effect, so phospholipase There is no need to perform a heat treatment in advance to deactivate the activity of A1 . In the method of the present invention, pancreatin is first added to cow brain, pig brain, chicken egg yolk, or soybean homogenate and reacted in water. Enzymes other than those mentioned above, such as ribonuclease, amylase, trypsin, chymotrypsin, lipase, and carboxypeptidase A
In order to suppress the activities of B and B, it is preferable to add calcium chloride and deoxycholic acid to the reaction system. And the above reaction is generally 5 to 50
The reaction is carried out at a temperature of 35°C, preferably 35°C, and a pH of 7.0 to 8.0, and the reaction is generally completed in 30 minutes to 12 hours. For example, when chicken egg yolk is used as a raw material and 0.1 to 2.0 g of pancreatin is used per chicken egg yolk (18 to 20 g), the reaction is completed in about 3 hours. After the reaction, the reaction solution is in a milky state, mostly consisting of proteins and fatty acids. By heating this reaction solution at 100 to 120°C, the protein is coagulated and the target substance is adsorbed therein. The target product can be isolated and collected by taking this coagulated protein and using conventional methods. For example, the coagulation protein obtained above can be mixed with methanol, ethanol,
Suspend in alcohol such as isopropanol to remove insoluble proteins, remove the solvent from the resulting extraction solution under reduced pressure, add a mixed solvent of halogenated hydrocarbons, alcohol, and water to the residue, and add organic Separate the layers. Then, the solvent was distilled off under reduced pressure.
Furthermore, in order to remove fatty acids, neutral fat sphingomyelin and oligopeptides, methanol,
Highly purified lysolecithin can be easily obtained by performing an extraction process with an alcohol such as ethanol and a hydrocarbon solvent such as n-hexane or cyclohexane, followed by solvent separation with an alcohol such as propanol and ethanol. .
次に実施例を挙げて本発明を説明する。 Next, the present invention will be explained with reference to Examples.
実施例 1
市販の鶏卵100個から卵黄のみを分取し、蒸留
水2.5に分散させる。あらかじめ、塩化カルシ
ウム二水塩4.4gを蒸留水200mlに溶解させたも
の、デオキシコール酸ナトリウム5.0gを蒸留水
200mlに溶解させたもの、及びパンクレアチン
(和光純薬製)100gを蒸留水200mlを懸濁させて
おいたものを、上記分散液中に添加し、30〜35℃
で3時間攬拌する。次に、反応液を塩化カルシウ
ムを溶かした水浴上で105〜110℃で3時間加熱す
る。放冷後、遠心脱水を行なつて、1.1Kgの黄褐
色物質を得る。これにメタノール1.2を加え、
室温下で30分間攬拌後、不溶物をロ別する。更に
これにメタノール1.6,1.6,1.0を加え、抽出を
くり返し、抽出液を集めて常圧下で2まで濃縮
させる。次いでクロロホルム2と水1を加
え、クロロホルム層を分取する。さらに水層にク
ロロホルムを400ml加えてクロロホルム層を分取
し、得られたクロロホルム溶液をあわせて減圧下
に溶媒を留去し480gの褐色物質を得る。(この褐
色物質を、粗製物1とする。)
次に、この粗製物1に80%メタノール水溶液1
及びn―ヘキサン400mlを加え、下層を分取
し、更に上層溶液に80%メタノール水溶液500ml
を加え、下層を分取する。得られたメタノール水
溶液をあわせて減圧下に溶媒を留去する。残渣に
エタノール200mlを加え、不溶物をロ別しロ液か
ら減圧下に溶媒を留去し、続いてイソプロパノー
ル200mlを加え、不溶物をロ別する。ロ液から減
圧下に溶媒を留去し、更にトルエンと共沸させる
ことにより脱水処理を行なえば淡黄色物質133g
を得る。これをピリジン及びエタノールからそれ
ぞれ1回ずつ再結晶すれば白色無定形晶状のリゾ
レシチン29gを得る。(尚、鶏卵黄1個中には、
レシチンが500〜700mg含まれているといれてい
ることから鶏卵黄1個に600mlのレシチンが含ま
れているとすれば、本実施例の収率は71.4%であ
る。)
IR(KBr)cm-1 1720,1460,1235,
1080,1050,960
NMR(CDC18)τ値 6.10(9H)6.80(9H)
7.65(2H)8.70(27H)
9.10(3H)
旋光度
〔α〕20/D=−2.75(C=11.5,CHC13:
CH3 OH=4:1)
〔α〕20/D=−0.66(C=10.6,CHC13:
CH3 OH=1:1)
実施例 2
実施例1で得られた粗製物1480gに、ピリジ
ン800mlを加え加熱溶解させる。一晩放置後、析
出している結晶をロ取し、これにエタノール200
mlを加えた後、不溶物をロ別し、ロ液にエーテル
500mlをすばやく加えると、白色結晶37gが析出
してくる。これをロ取し、ピリジン及びエタノー
ルからそれぞれ1回ずつ再結晶を行なえば、白色
無定形晶状のリゾレシチン2gを得る。(実施例1
と同様に考えると収率は78.8%である。)Example 1 Only the egg yolk is separated from 100 commercially available chicken eggs and dispersed in 2.5 liters of distilled water. Dissolve 4.4 g of calcium chloride dihydrate in 200 ml of distilled water and 5.0 g of sodium deoxycholate in distilled water.
200 ml of pancreatin (Wako Pure Chemical Industries, Ltd.) and 100 g of pancreatin (manufactured by Wako Pure Chemical Industries, Ltd.) suspended in 200 ml of distilled water were added to the above dispersion and heated to 30-35°C.
Stir for 3 hours. Next, the reaction solution is heated at 105 to 110°C for 3 hours on a water bath in which calcium chloride is dissolved. After cooling, centrifugal dehydration is performed to obtain 1.1 kg of a yellow-brown substance. Add 1.2 methanol to this,
After stirring at room temperature for 30 minutes, filter out insoluble materials. Furthermore, methanol 1.6, 1.6, 1.0 is added to this, the extraction is repeated, and the extracts are collected and concentrated under normal pressure to a volume of 2. Next, 2 parts of chloroform and 1 part of water are added, and the chloroform layer is separated. Furthermore, 400 ml of chloroform is added to the aqueous layer, the chloroform layer is separated, and the obtained chloroform solution is combined and the solvent is distilled off under reduced pressure to obtain 480 g of a brown substance. (This brown substance is referred to as crude product 1.) Next, add 1 part of 80% methanol aqueous solution to this crude product 1.
Add 400ml of n-hexane, separate the lower layer, and add 500ml of 80% methanol aqueous solution to the upper layer solution.
Add and separate the lower layer. The resulting methanol aqueous solution was combined and the solvent was distilled off under reduced pressure. Add 200 ml of ethanol to the residue, filter out the insoluble materials, and distill off the solvent from the filtrate under reduced pressure. Next, add 200 ml of isopropanol and filter out the insoluble materials. If the solvent is distilled off from the filtrate under reduced pressure and then dehydrated by azeotroping with toluene, 133g of pale yellow substance is obtained.
get. This is recrystallized once each from pyridine and ethanol to obtain 29 g of white amorphous crystalline lysolecithin. (In addition, in one chicken egg yolk,
It is said that 500 to 700 mg of lecithin is contained, so if one chicken egg yolk contains 600 ml of lecithin, the yield in this example is 71.4%. ) IR (KBr) cm -1 1720, 1460, 1235, 1080, 1050, 960 NMR (CDC1 8 ) τ value 6.10 (9H) 6.80 (9H) 7.65 (2H) 8.70 (27H) 9.10 (3H) Optical rotation [α ] 20/D = -2.75 (C = 11.5, CHC1 3 :
CH 3 OH = 4:1) [α] 20/D = -0.66 (C = 10.6, CHC1 3 :
CH 3 OH = 1:1) Example 2 To 1480 g of the crude product obtained in Example 1, 800 ml of pyridine was added and dissolved by heating. After standing overnight, filter out the precipitated crystals and add 200 ml of ethanol to it.
ml, filter out the insoluble matter and add ether to the filtrate.
When 500ml is quickly added, 37g of white crystals precipitate out. This is collected and recrystallized once each from pyridine and ethanol to obtain 2 g of lysolecithin in the form of white amorphous crystals. (Example 1
Considering the same way, the yield is 78.8%. )
Claims (1)
に、豚すい臓抽出酵素パンクレアチンを作用さ
せ、反応後加熱処理することを特徴とする天然型
リゾレシチン(リゾホスフアチジルコリン)の製
造法。 2 鶏卵黄ホモジネートを用いる特許請求の範囲
第1項記載の天然型リゾレシチンの製造法。 3 豚すい臓抽出酵素パンクレアチンを作用させ
る温度が、15〜50℃である特許請求の範囲第1項
記載の天然型リゾレシチンの製造法。 4 加熱処理を50〜120℃の温度で行う特許請求
の範囲第1項記載の天然型リゾレシチンの製造
法。[Scope of Claims] 1. A natural lysolecithin (lysophosphatidylcholine) characterized in that cow brain, pig brain, chicken egg yolk or soybean homogenate is reacted with pancreatin, an enzyme extracted from pig pancreas, and heat-treated after the reaction. manufacturing method. 2. The method for producing natural lysolecithin according to claim 1, using chicken egg yolk homogenate. 3. The method for producing natural lysolecithin according to claim 1, wherein the temperature at which the porcine pancreas extract enzyme pancreatin is applied is 15 to 50°C. 4. The method for producing natural lysolecithin according to claim 1, wherein the heat treatment is performed at a temperature of 50 to 120°C.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7151778A JPS55315A (en) | 1978-06-15 | 1978-06-15 | Novel preparation of natural lysolecithin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7151778A JPS55315A (en) | 1978-06-15 | 1978-06-15 | Novel preparation of natural lysolecithin |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS55315A JPS55315A (en) | 1980-01-05 |
JPS6130555B2 true JPS6130555B2 (en) | 1986-07-14 |
Family
ID=13462978
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP7151778A Granted JPS55315A (en) | 1978-06-15 | 1978-06-15 | Novel preparation of natural lysolecithin |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS55315A (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60163888A (en) * | 1984-02-03 | 1985-08-26 | Pola Chem Ind Inc | Production of lipid component |
JPH0761274B2 (en) * | 1986-08-11 | 1995-07-05 | 旭電化工業株式会社 | Enzymatic degradation method of phospholipid |
JPH0620525B2 (en) * | 1986-11-26 | 1994-03-23 | キユーピー株式会社 | Method of manufacturing emulsified material |
JP2792091B2 (en) * | 1989-04-12 | 1998-08-27 | 日本油脂株式会社 | Method for producing 1-acyl-lysophosphatidylcholine |
CN111363771B (en) * | 2020-03-18 | 2023-03-14 | 湖北瑞邦生物科技有限公司 | Production process of pig brain extract with strong oxidation resistance and pig brain extract |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4034124A (en) * | 1974-11-25 | 1977-07-05 | Lever Brothers Company | Emulsions |
-
1978
- 1978-06-15 JP JP7151778A patent/JPS55315A/en active Granted
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4034124A (en) * | 1974-11-25 | 1977-07-05 | Lever Brothers Company | Emulsions |
Also Published As
Publication number | Publication date |
---|---|
JPS55315A (en) | 1980-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100331932B1 (en) | A method for preparing lysophosphatidylethanolamine | |
JPH0249593A (en) | Production of lysolecithin | |
JP5113042B2 (en) | Process for the preparation and isolation of phosphatides | |
JPS6130555B2 (en) | ||
JP2001526026A (en) | Extraction method and use of hatching liquid from Atlantic salmon | |
US5153125A (en) | Process for producing lysophospholipids-containing phospholipids with reduced neutral lipid content | |
JPH0211234B2 (en) | ||
EP0082818B1 (en) | Process to obtain human lipids and lacto-n-norhexaosyl ceramide | |
US5100787A (en) | Method for preparing highly purified phosphatidylinositol | |
Paltauf et al. | [12] Preparation of alkyl ether and vinyl ether substrates for phospholipases | |
JP3032357B2 (en) | Fractionation and purification method of phospholipid fraction | |
JPH03123493A (en) | Hydrolysis of diacylglyceroline lipid | |
JP2731852B2 (en) | A new method for producing lysophosphatidylcholine. | |
JPS63123389A (en) | Production of phospholipid-d-serine derivative by enzymatic method | |
JP7222551B2 (en) | Method for producing cyclic sodium phosphatidate | |
US3862968A (en) | Process of methylating cephalins | |
JPH0725877A (en) | Production of hemin, proptoporphyrin diester and photoporphyrin disodium salt | |
JPH0662648B2 (en) | Method for producing high-purity lecithin | |
JPH0761274B2 (en) | Enzymatic degradation method of phospholipid | |
KR100450308B1 (en) | Process for the crystallization of phosphatidyl choline from yolk | |
JPS60130539A (en) | Preparation of optically active styrene halohydrin | |
JPH01187089A (en) | Production of palmitoleic acid and glyceride thereof | |
JPS6259287A (en) | Production of phospholipid essentially free from lysophosphatidylcholine | |
JP2792091B2 (en) | Method for producing 1-acyl-lysophosphatidylcholine | |
JP3022131B2 (en) | Phospholipase A1 and its use |